An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (NCT07027527)
A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).
Who can join: Review the eligibility criteria below.
Location: Investigational Site — Darlinghurst, New South Wales
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Investigational Site — Darlinghurst, New South Wales
- Investigational Site — Kogarah, New South Wales
- Investigational Site — Westmead, New South Wales
- Investigational Site — Woolloongabba, Queensland
- Investigational Site — Carlton, Victoria
- Investigational Site — East Melbourne, Victoria
- Investigational Site — Mitcham, Victoria
- Investigational Site — Parkville, Victoria
- Investigational Site — Fremantle, Western Australia
- Investigational Site — London, Ontario
- Investigational Site — Peterborough, Ontario
- Investigational Site — Richmond Hill, Ontario
- Investigational Site — Toronto, Ontario
- Investigational Site — Toronto, Ontario
- Investigational Site — Toronto, Ontario
- Investigational Site — Montreal, Quebec
- Investigational Site — Québec, Quebec
- Investigational Site — Sherbrooke, Quebec
- Investigational Site — Hamilton, Waitako
- Investigational Site — Auckland,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.